SEC Form 3 · accession 0001213900-15-009556
RELMADA THERAPEUTICS, INC. · RLMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lisa Nolan
Officer — Chief Business Officer
Period of report
Dec 14, 2015
Accepted (ET)
Dec 17, 2015 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001553643
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 10,000 | D | ||
| Common StockF1 | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF2 | $13.50 | holding | — | — | — | Apr 6, 2015 | Apr 6, 2025 | Common Stock | 50,000 | — | D |
Explanation of responses
- F130,000 shares of restricted stock granted on April 6, 2015. A total of 25% of the stock will vest one year from the grant date, and the remaining 75% shall vest in equal quarterly increments of 6.25% of the initial option grant over the following three year period.
- F2Options granted on April 6, 2015 to purchase an aggregate of 50,000 shares of common stock. A total of 25% of the options will vest one year from the grant date, and the remaining 75% shall vest in equal quarterly increments of 6.25% of the initial option grant over the following three year period.